Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • The Right Platform for This Moment

    Amid the evolving economic landscape of the past few years and continued shifts in 2025, we at William Blair have worked hard to expand our platform and provide creative solutions.

    Watch the video

  • Cash is Still King, Especially During the Great Iberian Blackout (El Apagón)

    The complete power outage across the Iberian Peninsula last week was a wake-up call. William Blair’s Richard de Chazal outlines five lessons to take away from the event.

    Read more

  • Roper Technologies, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Roper Technologies, Inc. (ROP $557.59), a leading operator and acquirer of high-quality vertical software assets across multiple industries.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures